Healthtech Partnering Week March Schedule

4 Feb

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claireHealthtech Partnering Week, the premier partnering experience for early-stage companies innovating life science and healthcare, is fast approaching! We are thrilled to announce the schedule for the week. If you haven’t signed up yet, there’s still time to save on early bird rates – sign up by February 19 to save and start meeting your fundraising goals!

Check Out Our Live Panel Schedule for Healthtech Partnering Week, March 15-19

Digital RESI

Digital Redefining Early Stage Investments (RESI) is Life Science Nation’s flagship partnering event, featuring active, early-stage investors across biotech, medtech, and healthtech. RESI seeks to highlight the latest investment trends in order to advance cross-border, cross-domain partnerships.

Time (EST) Monday, March 15 Tuesday, March 16 Wednesday, March 17
10:00 AM Early Stage Therapeutics Investors Panel Diagnostics Investors Panel Tools and R&D Services Panel
1:00 PM Innovator’s Pitch Challenge Session I Innovator’s Pitch Challenge Session III Innovator’s Pitch Challenge Session V
2:00 PM Medical Devices Investors Panel Combination Devices Panel Digital Health Panel
3:00 PM Innovator’s Pitch Challenge Session II Innovator’s Pitch Challenge Session IV Innovator’s Pitch Challenge Session VI
4:00 PM Digital Therapeutics Panel Cell & Gene Therapy Panel

4D Meets AI

4D Meets AI panels host active investors and their portfolio companies to discuss funding, partnerships, and the future of AI in each one of the 4Ds: drugs, devices, diagnostics, and digital health.

Time (EST) Thursday, March 18 Friday, March 19
9:00 AM Drugs Panel Diagnostics Panel
1:00 PM Innovator’s Pitch Challenge Session I Innovator’s Pitch Challenge Session II
2:00 PM Devices Panel Digital Health Panel
More Content Panels to Come
Stay Tuned for the 4D Meets AI Workshops

Longevity, Health & Innovation

Longevity, Health & Innovation features two tracks: Investment Ecosystem and Market Overview. The panels, co-organized with Mary Furlong & Associates are designed to provide a whole picture of the longevity marketplace, focusing on early-stage investments and strategic partnerships, as well as technology, innovation, regulation, and advancements in the field.

Time (EST) Thursday, March 18 Friday, March 19
10:00 AM Digital Health for the Elderly Panel Investing in New, Now, and Next Panel
11:00 AM Early Detection of CNS Disorders Panel Therapeutics for Thriving Panel
12:00 PM Innovator’s Pitch Challenge Session I Innovator’s Pitch Challenge Session II
3:00 PM Stakeholders in the Longevity Marketplace Panel Investors and Entrepreneurs Share the Latest Trends Panel
4:00 PM Care Economy Panel Health Technology Panel

Introducing the Age-Tech Bulletin Newsletter

4 Feb

By Shelly Mittal, Investor Research Analyst, LSN

Life Science Nation (LSN) is thrilled to announce the Age-Tech Bulletin, a weekly newsletter featuring investors and strategic partners seeking to invest in early-stage senior healthcare and longevity companies. This newsletter provides the latest investment mandates, enabling fundraising CEOs to connect with strategic partners active in their industry. Age-Tech Bulletin also provides opportunities for investors, fundraising CEOs, and strategic partners to get involved with the Longevity, Health & Innovation (LHI) digital partnering conference: a unique partnering experience, co-organized with Mary Furlong & Associates, connecting longevity industry leaders with promising age-tech companies.

The Age-Tech Bulletin highlights networking opportunities exclusively available through our industry leaders, connecting investors and start-ups to facilitate early-stage deals for seniors to live longer and healthier lives.

Check out our most recent issue and sign up to receive the weekly Age-Tech Bulletin and find out how to get involved with Longevity, Health & Innovation, March 18-19, 2021.

Hot Investor Mandate: Asia Venture Capital Fund Invests Up to $25M in Therapeutics & Medical Device Companies with Strong Interest in Oncology, Immunology, CNS

4 Feb

A life sciences venture capital fund headquartered in Asia is actively seeking investment opportunities. On average, the size of investment is $5-25M in venture rounds. The firm prefers to act as the lead investor but is also open to co-investing. The firm looks for companies located around the globe, with a preference in the US and China. The firm is actively seeking new investment opportunities.

The firm is focused on Therapeutics and Medical Devices opportunities. The firm’s core focused therapeutic areas include oncology, immunology and CNS diseases, but is also opportunistic in other indications (modality agnostic) and willing to consider orphan indications. The firm is also interested in interventional, novel medical devices in cardiovascular, neuro-vascular diseases.

The firm prefers management team with strong scientific background and expertise, successful track records would be a plus but is not required. The firm generally takes a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA VC Firm Invests Up to $50M in Growth Stage, Revenue Generating Companies with Strong Marketplace Validation

4 Feb

A USA-based firm makes equity investments in commercial stage (post regulatory approval) healthcare companies with meaningful revenue and traction. The firm typically invests between $15-$50m per company.

The firm invests exclusively in healthcare and is open to all sub-sectors within the industry. That said, the firm does not invest in pre-revenue companies or those with regulatory risk; investments are made in revenue-generating companies with products that have already received regulatory approval or which do not require regulatory approval. The firm looks for companies with meaningful marketplace validation and growing revenues, where the firm’s investment could help to accelerate the adoption.

The firm prefers to invest in management teams with experience in leading and growing businesses of scale and relevant industry experience.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Investment Firm Partnered with Family Office Invests in Early-Stage Therapeutics, Devices, Diagnostics Companies Across the USA

4 Feb

A firm dedicated to accelerating the growth of seed-stage life sciences companies operates in partnership with a USA-based family office. The firm invests $250-500K in early financing rounds within high-quality syndicates. The firm invests in companies based in the U.S.

The firm is seeking investments in next-generation therapeutics, medical device, and diagnostics companies. Within the therapeutics sector, the firm invests in cell, gene, oligonucleotide, and microbial therapies, as well as other targeted therapies for well-defined diseases. Typical investments occur at the stage of lead optimization and IND-enabling studies. Within MedTech, the firm invests in platforms leveraging novel biological insights, including cellular and molecular diagnostics, biomaterials, and bio-active implants. Typical investment stage is during late-stage product development approaching regulatory clearance and commercialization.

The firm does not have any specific company or management team requirements. The firm is a strategic as well as financial investor, helping companies develop relationships and accelerate growth.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA Family Office Actively Seeking Medical Device & Diagnostics Investment Opportunities, as well as AI-Related Technologies

4 Feb

A family office based in the USA looks to invest in medical devices and diagnostics, but will also consider therapeutics and digital health. The firm prefers company that have some proof of concept data, with some animal studies complete, and will invest through to clinical-stage companies. The firm generally co-invests in a syndicate, and will invest between $100-500K, depending on the stage of development of the company. The firm is currently interested in investing in companies located in North America.

The firm is focused primarily on medical devices and diagnostics, but will consider therapeutics, if they are first in class, and digital health, with a focus on AI-related technologies. The firm has focused on technologies related to oncology, diabetes and kidney diseases, but will consider other indications as well.

The firm is interested in companies with strong management teams. As the firm will generally co-invest, board representation is not usually required after investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Mandates: US-Based Angel Group

1 Feb

An angel investor group looks to invest in companies that help solve societal problems and will either invest in an existing company or help form a company around a technology that addresses a need. With a current focus on healthcare, the firm looks for technologies with a social impact, such as those addressing chronic pain management, the opioid crisis or issues facing the aging population. The firm invests in seed/angel rounds and may invest in follow on rounds, generally investing between $20K-300K. The firm will lead a seed round, or co-invest in an angel round. The firm is seeking to invest in companies with high-growth potential in the US, but will invest in Canada as well. The firm will also partner with medical societies or academic centers to transfer technologies into new ventures.

The firm is opportunistic with regards to sector and indication, and will invest in therapeutics, devices, diagnostics or digital health companies in any indication that meets their mission of social impact and investment thesis around high growth. The firm has historically invested in companies within neuroscience but is also open to other indications such as cardiovascular disease and diabetes. The firm generally takes a board or observer seat after investing, and can provide interim management support as well.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

← Older Entries
Newer Entries →